Depressive Disorder

4
Pipeline Programs
5
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
3 programs
1
2
SaredutantPhase 31 trial
Saredutant succinatePhase 35 trials
SSR149415Phase 21 trial
Active Trials
NCT00361491Completed324Est. Sep 2007
NCT00429260Completed125Est. Jun 2007
NCT00250653Completed365Est. Apr 2007
+4 more trials
Teva
TevaIsrael - Petach Tikva
1 program
1
Bupropion HClPhase 11 trial
Active Trials
NCT01046214Terminated8
Pfizer
PfizerNEW YORK, NY
1 program
Computerized Decision Support System for DepressionN/A1 trial
Active Trials
NCT00551083Completed60Est. Jun 2006
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
GlademN/A1 trial
Active Trials
NCT02231268Completed546
Neuroelectrics
NeuroelectricsSpain - Barcelona
1 program
transcranial direct current stimulationN/A1 trial
Active Trials
NCT06165445CompletedEst. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiSaredutant
SanofiSaredutant succinate
SanofiSaredutant succinate
SanofiSaredutant succinate
SanofiSaredutant succinate
SanofiSaredutant succinate
SanofiSSR149415
TevaBupropion HCl
Neuroelectricstranscranial direct current stimulation
PfizerComputerized Decision Support System for Depression
Boehringer IngelheimGladem

Clinical Trials (11)

Total enrollment: 3,272 patients across 11 trials

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

Start: Jan 2007Est. completion: Jun 2007125 patients
Phase 3Completed
NCT00250653SanofiSaredutant succinate

A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

Start: May 2005Est. completion: Apr 2007365 patients
Phase 3Completed
NCT00250614SanofiSaredutant succinate

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Start: Apr 2005Est. completion: Oct 2006452 patients
Phase 3Completed
NCT00250601SanofiSaredutant succinate

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Start: Apr 2005Est. completion: Jul 2007460 patients
Phase 3Completed
NCT00250627SanofiSaredutant succinate

An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Start: Dec 2004Est. completion: Dec 2006465 patients
Phase 3Completed
NCT00256113SanofiSaredutant succinate

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Start: Dec 2004Est. completion: Dec 2006467 patients
Phase 3Completed

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder

Start: Aug 2006Est. completion: Sep 2007324 patients
Phase 2Completed
NCT01046214TevaBupropion HCl

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Start: Jan 20108 patients
Phase 1Terminated
NCT06165445Neuroelectricstranscranial direct current stimulation

Optimizing tDCS Protocol for Clinical Use in Major Depressive Disorder

Start: Jun 2021Est. completion: Mar 2023
N/ACompleted
NCT00551083PfizerComputerized Decision Support System for Depression

Efficacy Study of a Computer Decision Support System to Treat Depression

Start: Mar 2005Est. completion: Jun 200660 patients
N/ACompleted

Observational Study to Assess a 6-months Treatment With Gladem

Start: Sep 2000546 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space